PathMaker Neurosystems Announces Publication of First Study Demonstrating Increased Survival in an ALS Mouse Model After Treatment With Non-Invasive Neuromodulation
This important study marks the first demonstration of any non-invasive neuromodulation technique delivering statistically significant survival benefits in an ALS mouse model. The results are compelling, with treated mice exhibiting a 74% increase in survival time from disease onset compared to untreated counterparts.
The published paper, ' Multi-path direct current spinal stimulation extended survival in the SOD1-G93A model of amyotrophic lateral sclerosis,' has as senior author, Dr. Zaghloul Ahmed, Professor and Chairman, Department of Physical Therapy and Professor, Center for Developmental Neuroscience, CUNY and Scientific Founder of PathMaker Neurosystems. Beyond extending survival and mitigating motor neuron degeneration, this NIH-funded research highlights that Multi-Site DCS treatment also reduced spinal excitability, decelerated motor dysfunction progression, activated protein degradation pathways and lowered SOD1 protein levels in motor neurons.
'These results provide compelling evidence that our non-invasive treatment approach can meaningfully impact disease progression,' said Nader Yaghoubi, M.D., Ph.D., Co-Founder and Chief Executive Officer of PathMaker Neurosystems. 'The mechanistic insights from this paper underscore the potential of non-invasive Multi-Site DCS as a transformative disease-modifying intervention for ALS. Our ongoing efforts are directed towards translating this innovative treatment into clinical development, with the CALM trial, Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability, our second ALS clinical trial, now in progress ( NCT06649955 ). This trial, funded by the U.S. Department of Defense ALSRP program, represents a significant advancement in our journey to bring this novel modality to clinical use.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems is a clinical-stage neuromodulation company developing a breakthrough non-invasive approach to the treatment of amyotrophic lateral sclerosis (ALS). More than 34,000 people in the U.S. and 350,000 people worldwide are estimated to suffer from ALS. PathMaker is collaborating with world-class institutions to develop and bring to market first-in-class products for treating ALS and other neurological disorders with very high unmet medical need. The MyoRegulator® platform is based on PathMaker's proprietary technology for multi-site direct current stimulation (Multi-Site DCS). MyoRegulator® has been previously designated by the US Food and Drug Administration (FDA) as a 'FDA Breakthrough Device.' MyoRegulator® and MyoRegulator® ALS are investigational medical devices and are limited by Federal law to investigational use only. For more information, please visit the company website at www.pmneuro.com.
Source: PathMaker Neurosystems Inc.
Media contact: PathMaker PR
(617) 535-7696
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
LISTEN: How Noah Hawley and FX Brought ‘Alien: Earth' to Life; Kevin Feige Gets Candid as Comic Con Approaches
About eight years ago, multihyphenate Noah Hawley wrote a five-page pitch for FX on what he would do with the 'Alien' franchise if he ever got the chance to work in the world established in 1979 by Ridley Scott's seminal film. Next month, FX will unveil its wildly ambitious, first-ever TV series take on the sci-fi franchise that has spawned eight other films across the past five decades. On the latest episode of the 'Daily Variety' podcast, Daniel D'Addario, Variety's chief correspondent, offers insights into his inside look at the making of 'Alien: Earth' that is featured as 's July 23 cover story. More from Variety 'Alien: Earth' Is Wildly Ambitious, Expensive and Stars a Talented Actor Who Refuses to Play by Hollywood's Rules. Inside FX's Risky Bet for a New Blockbuster Series Neon's 'Next Wave of Horror' Comic-Con Panel to Feature 'Together' Stars Alison Brie and Dave Franco, Osgood Perkins, Tatiana Maslany and More (EXCLUSIVE) Scott Free Eyes Further Series Adaptations of Ridley Scott and Tony Scott Movies Following 'Alien: Earth' and 'Blade Runner 2099' D'Addario reports that all of the major components of Hawley's eight-year-old outline made it into the final series, which drops on FX and Hulu Aug. 12. That's a testament to the strength of the writer-producer's vision for adapting 'Alien' as a TV series for the present day. D'Addario notes that Hawley is a famously prolific 'idea machine' who has the trust of FX leadership. That's important given all that FX has riding on 'Alien: Earth,' which has topped the budget of FX's previous most expensive series. 'He's a novelist. He's written and directed feature films, and he just has the ability to work through this IP world without having it feel like a crass brand extension. It's 'Alien,' but it is fundamentally a Noah Hawley show as well,' D'Addario says. Also featured in today's episode is a conversation with Adam B. Vary, Variety's senior entertainment writer, about what to expect from San Diego Comic Con, which begins on July 24 and is always a mile-marker for studios and networks. Vary also discusses his recent sit down with Marvel chief Kevin Feige, who delivered a candid assessment of the studio's recent struggles. Feige cited a startling statistic that illustrated how Marvel simply became overextended in recent years as it ramped up production to feed series and movies to Disney+, which has been an enormous priority for parent company Disney. From 2008 to 2019, Marvel produced about 50 total hours worth of film and TV content. In the last six years, Marvel has produced more than 120 hours. 'That massive increase in volume really diluted the brand, diluted their quality. At one point he said, for the first time, quantity trumped quality.' And, that's a pretty blunt assessment for what went wrong,' Vary says. As for Comic Con, Vary predicts it will be less of a launchpad than in the past as Marvel is not hosting its usual state-of-the-industry presentation (hence Feige's charm offensive with journalists), nor does DC Studios have a big presence this year. 'It's generally going to be a little bit of a quieter Comic Con,' Vary says. Daily Variety Best of Variety New Movies Out Now in Theaters: What to See This Week 'Harry Potter' TV Show Cast Guide: Who's Who in Hogwarts? Final Emmy Predictions: Talk Series and Scripted Variety - New Blood Looks to Tackle Late Night Staples Solve the daily Crossword
Yahoo
34 minutes ago
- Yahoo
Blue Origin's Latest Launch Sends Crypto Billionaire Justin Sun to Space After He Bid $28M for Seat on 10-Minute Flight
"When I look at it from space, Earth is so small and that's our home," Sun said after his brief trip on the New Shepard rocketNEED TO KNOW Blue Origin, founded by Jeff Bezos, brought another crew to space The crew included cryptocurrency billionaire Justin Sun, who bid $28 million for the seat on the rocket, along with five others The mission was the 34th flight for the New Shepard programSix more people have gone to space thanks to Blue Origin. The space technology company, founded by Jeff Bezos, brought another crew to space on Sunday, August, 3, including cryptocurrency billionaire Justin Sun. The mission — known as NS-34 —was the 34th flight for the New Shepard program, according to the Blue Origin website. The crew launched from West Texas on the New Shepard rocket at 8:43 a.m. local time, per Blue Origin's X. Another post confirmed that the flight controllers "confirmed capsule separation" about three minutes later, which means the crew experienced "weightlessness." "Crew Capsule apogee confirmed," Blue Origin wrote at 8:47 a.m., before confirming that the crew had "landed" mere minutes later. Another update stated that the aircraft reached touchdown at 8:53 a.m., after a total of 10 minutes. "Welcome back, NS-34 crew," the company wrote on social media. Blue Origin reported that the company "successfully completed its 14th human spaceflight" following the flight. Along with Sun, the crew included real estate investor Arvi Bahal, Turkish businessman Gökhan Erdem, meteorologist Deborah Martorell, educator Lionel Pitchford and entrepreneur J.D. Russell. Sun won a bid for his seat on the New Shepard in 2021. He bid $28 million for the seat, according to Bloomberg and The outlet reported that he was supposed to be on the landmark flight on July 20, 2021, in recognition of the 52nd anniversary of the Apollo 11 moon landing, but was unable to make the trip due to a scheduling conflict. "It was an honor to see so many nations represented on our flight today. The view of our fragile planet from space has a unifying effect on all who witness it, and I am always eager to see how our astronauts use this experience for the benefit of Earth," said Phil Joyce, Senior Vice President of Blue Origin, in a statement. Per Blue Origin's website, the New Shepard is a "fully reusable, suborbital rocket system built for human flight from the beginning." During the autonomous aircraft's 11-minute trip, those onboard pass the Kármán line into space. The crew experiences "several minutes of weightlessness and witnessing life-changing views of Earth." Singer Katy Perry, broadcast journalist Gayle King, philanthropist Lauren Sánchez, former NASA rocket scientist Aisha Bowe, bioastronautics research scientist Amanda Nguyen and film producer Kerianne Flynn notably went to space on the New Shepard in April as part of its 31st launch. Sun reflected on his brief journey into space in an interview shared on his Instagram. "For this mission, I've waited for four years but we've finally delivered it. I really appreciate Mr. Bezos and his team for making this possible. And thank you dad and mom for bringing me to Earth," he said. "When I look at it from space, Earth is so small and that's our home. We definitely need to do whatever we can do to protect it," Sun added. The entrepreneur made headlines in November 2025 for buying viral artwork depicting a yellow banana duct-taped to a wall. 'This is not just an artwork; it represents a cultural phenomenon that bridges the worlds of art, memes and the cryptocurrency community,' Sun wrote on X. 'I believe this piece will inspire more thought and discussion in the future and will become a part of history.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "I am honored to be the proud owner of the banana 🍌 and look forward to it sparking further inspiration and impact for art enthusiasts around the world," Sun continued. He later consumed the banana used in the artwork, writing in another X post, "To be honest, for a banana with such a back story, the taste is naturally different from an ordinary one. I could discern a hint of what Big Mike bananas from 100 years ago might have tasted like." Read the original article on People Solve the daily Crossword
Yahoo
39 minutes ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
